Carboplatin and Doxorubicin Combination Chemotherapy for the Treatment of Appendicular Osteosarcoma in the Dog

Journal of Veterinary Internal Medicine

Volumn 17, Issue 2, 2003, Pages 199-205

  Bailey, Dennis ^a,b   Erb, Hollis ^b   Williams, Laurel ^a   Ruslander, David ^a   Hauck, Marlene ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

Bone cancer; Summation dose intensity; Tolerable dose diagram

Indexed keywords

CARBOPLATIN; DOXORUBICIN; ANTINEOPLASTIC AGENT;

AMPUTATION; APPENDICULAR OSTEOSARCOMA; ARTICLE; CANCER CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOG; GASTROINTESTINAL DISEASE; HAZARD ASSESSMENT; LIMB SALVAGE; METASTASIS; NONHUMAN; OSTEOSARCOMA; SURVIVAL RATE; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; ANIMAL; CLINICAL TRIAL; DOG DISEASE; DOSE RESPONSE; DRUG COMBINATION; FEMALE; MALE; SURVIVAL;

CANIS FAMILIARIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; MALE; OSTEOSARCOMA; SURVIVAL ANALYSIS;

EID: 0037642506     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2003)017<0199:CADCCF>2.3.CO;2     Document Type: Article

References (45)

1. Spodnick GJ, Berg J, Rand WM, et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc 1992;200:995-999.
2. Shapiro W, Fossum TW, Kitchell BE, et al. Use of cisplatin for treatment of appendicular osteosarcoma in dogs. J Am Vet Med Assoc 1988;192:507-511.
3. Mauldin GN, Matus RE, Withrow SJ, et al. Canine osteosarcoma: Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Intern Med 1988;2:177-180.
4. Thompson JP, Fugent MJ. Evaluation of survival times after limb amputation with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979-1990). J Am Vet Med Assoc 1992;200:531-533.
5. Berg J, Weinstein MJ, Schelling SH, Rand WM. Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987-1990). J Am Vet Med Assoc 1992;200:2005-2008.
6. Morello E, Buracco P, Martano M, et al. Bone allografts and adjuvant cisplatin for the treatment of canine appendicular osteosarcoma in 18 dogs. J Small Anim Pract 2001;42:61-66.
7. Kraegel SA, Madewell BR, Simonson E, Gregory CR. Osteogenic sarcoma and cisplatin chemotherapy in dogs: 16 cases (1986-1989). J Am Vet Med Assoc 1991;199:1057-1059.
8. Straw RC, Withrow SJ, Richter SL, et al. Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med 1992;5:205-210.
9. Bergman PJ, MacEwen EG, Kurzman ID, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 1996;10:76-81.
10. Berg J, Weinstein MF, Springfield DS, et al. Response of osteosarcoma in the dog to surgery and chemotherapy with doxorubicin. J Am Vet Med Assoc 1995;206:119-124.
11. Berg J, Gebhardt MC, Rand WM. Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma. Cancer 1997;79:1343-1350.
12. Chun R, Kurzman ID, Couto CG, et al. Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: A pilot study. J Vet Intern Med 2000;14:495-498.
13. Chun R, Kurzman ID, Couto CG, et al. A preliminary evaluation of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. Veterinary Cancer Society 17th Annual Conference, Chicago, IL, 1997.
14. Page RL, McEntee MC, George SL, et al. Pharmacokinetic and phase I evaluation of carboplatin in dogs. J Vet Intern Med 1993;7:235-240.
15. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999;17:409-422.
16. Browner WS, Black D, Newman TB, Hulley SB. Estimating sample size and power. In: Hulley SB, Cummings SR, eds. Designing Clinical Research. Baltimore, MD: Williams and Wilkins; 1988:139-150.
17. National Cancer Institute. Common toxicity criteria, version 2.0 [National Cancer Institute/Cancer Therapy Evaluation Program Web site]. March 23, 1998. Available at: http://ctep.cancer.gov/reporting/ctc.html. Accessed January 22, 2002.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
19. Dawson B, Trapp RG. Analyzing research questions about survival. In: Basic and Clinical Biostatistics, 3rd ed. New York, NY: Lange Medical Books; 2001:211-232.
20. Baar J, Tannock I. Analyzing the same data in two ways: A demonstration model to illustrate the reporting and misreporting of clinical trials. J Clin Oncol 1989;7:969-978.
21. Bell RS, Roth YF, Gebhardt MC, et al. Timing of chemotherapy and surgery in a murine osteosarcoma model. Cancer Res 1988;48: 5533-5538.
22. Ogilvie GK, Reynolds HA, Richardson RC, et al. Phase II evaluation of doxorubicin for treatment of various canine neoplasms. J Am Vet Med Assoc 1989;195:1580-1583.
23. Ogilvie GK, Straw RC, Jameson VJ, et al. Evaluation of single-agent chemotherapy for treatment of clinically evident osteosarcoma metastases in dogs: 45 cases (1987-1991). J Am Vet Med Assoc 1993;202:304-306.
24. Hahn KA, Richardson RC, Blevins WE, et al. Intramedullary cisplatin chemotherapy: Experience in four dogs with osteosarcoma. J Small Anim Pract 1996;37:187-192.
25. Simon R, Korn EL. Selecting drug combinations based on total equivalent dose (dose intensity). J Natl Cancer Inst 1990;82:1469-1476.
26. Korn EL, Simon R. Using the tolerable-dose diagram in the design of phase I combination chemotherapy trials. J Clin Oncol 1993;11:794-801.
27. Frei E, Elias A, Wheeler C, et al. The relationship between high-dose treatment and combination chemotherapy: The concept of summation dose intensity. Clin Cancer Res 1998;4:2027-2037.
28. Chun R, Garrett LD, Hanry C, et al. Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. Veterinary Cancer Society 21st Annual Conference, Baton Rouge, LA, 2001.
29. Gaver RC, George AM, Duncan GF, et al. The disposition of carboplatin in the Beagle dog. Cancer Chemother Pharmacol 1988;21:197-202.
30. Gralla EJ, Fleischman RW, Luthra YK, Stadnicki SW. The dosing schedule dependent toxicities of adriamycin in Beagle dogs and Rhesus monkeys. Toxicology 1979;13:263-273.
31. Loar AS, Susaneck SJ. Doxorubicin-induced cardiotoxicity in five dogs. Semin Vet Med Surg (Small Anim) 1986;1:68-71.
32. Arrington KA, Legendre AM, Tabeling GS, Frazier DL. Comparison of body surface area-based and weight-based dosage protocols for doxorubicin administration in dogs. Am J Vet Res 1994;55:1587-1592.
33. Ogilvie GK, Obradovich JE, Cooper MF, et al. Use of recombinant canine granulocyte colony-stimulating factor to decrease myelosuppression associated with the administration of mitoxantrone in the dog. J Vet Intern Med 1992;6:44-47.
34. Budd GT, Fanapathi R, Wood L, et al. Approaches to managing carboplatin-induced thrombocytopenia: Focus on the role of amifostine. Semin Oncol 1999;26(Suppl 7):41-50.
35. Wormer RB. Problems and controversies in the management of childhood sarcomas. Br Med Bull 1996;52:826-843.
36. Madewell BR, Leighton RL, Theilen GH. Amputation and doxorubicin for treatment of canine and feline osteogenic sarcoma. Eur J Cancer 1978;14:287-293.
37. Skipper HE. Dose intensity versus total dose of chemotherapy: An experimental basis. Important Adv Oncol 1990:43-64.
38. Ihnat MA, Lariviere JP, Warren AJ, et al. Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents. Clin Cancer Res 1997;3:1339-1346.
39. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer: Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000;11:265-283.
40. Ihnat MA, Nervi AM, Anthony SP, et al. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice. Oncol Res 1999;11:303-310.
41. Chaudhary PM, Roninson IG. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993;85:632-639.
42. Bader P, Fuchs J, Wenderoth M, et al. Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated into mice following treatment with adriamycin or cisplatin. Anticancer Res 1998;18:3127-3132.
43. Chu E, DeVita VT. Principles of cancer management: Chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer, Principles and Practice of Oncology, 6th ed. Philadelphia, PA: Lippincott; 2001:289-306.
44. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-1756.
45. Donahue A, McCune JS, Faucette S, et al. Measured versus estimated glomerular filtration rate in the Calvert equation: Influence on carboplatin dosing. Cancer Chemother Pharmacol 2001;47:373-379.